Trial Profile
An Investigator-Initiated, Open-label Study Evaluating the Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 19 Oct 2016 Results of pooled safety analysis from 12 Ustekinumab Crohn's Disease and Psoriatic Diseases trials (n=3636), presented at the 24th United European Gastroenterology Week
- 20 Jul 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.